Uncategorized
Amgen seeks to buoy Tepezza with injectable data in face of incoming competition
Amgen said that an injectable version of its eye drug Tepezza succeeded in a Phase 3 study for thyroid eye disease, setting up a showdown with Viridian Therapeutics, which last week also posted Phase 3 …